Employers and industry partners will find thought leadership, insights and opportunity to reflect as we recap the Business Group’s...

With a shifting coverage and regulatory landscape, there is an opportunity for employers to consider how medical cannabis fits...

A comprehensive look into prescription drug rebates, their unintended consequences and methods for evaluating their impact on...

HHS issues guidance on IDR enforcement and the Gag Clause Prohibition, addressing key compliance concerns for plan sponsors.

Though biosimilar approvals and utilization have increased, market dynamics have prevented employers from realizing their full...

With over a quarter of employers’ health care dollars (in the U.S.) attributed to payments for prescription drugs, growing...

As health care costs continue to rise, employers may consider a broader range of options to provide health benefits that balance...